Ganoderma lucidum exerts anti-tumor effects on ovarian cancer cells and enhances their sensitivity to cisplatin

International Journal of Oncology

Volumn 38, Issue 5, 2011, Pages 1319-1327

  Zhao, Sufen ^a,b   Ye, Gang ^a   Fu, Guodong ^a   Cheng, Jian Xin ^b   Yang, Burton B ^c   Peng, Chun ^a  

^a YORK UNIVERSITY   (Canada)

^b HEBEI MEDICAL UNIVERSITY   (China)

^c Sunnybrook Health Sciences Centre   (Canada)

Author keywords

Chemoresistant cells; Ganoderma; Ovarian cancer

Indexed keywords

CASPASE 3; CISPLATIN; GANODERMA LUCIDUM EXTRACT; PROTEIN KINASE B; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CELL ACTIVITY; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG SENSITIVITY; ENZYME ACTIVATION; FEMALE; GANODERMA LUCIDUM; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPHEROID CELL; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DRUG SYNERGISM; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; REISHI;

EID: 79955009117     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.965     Document Type: Article

References (43)

1. Sanodiya BS, Thakur GS, Baghel RK, Prasad GB and Bisen PS: Ganoderma lucidum: a potent pharmacological macrofungus. Curr Pharm Biotechnol 10: 717-742, 2009.
2. Chen HS, Tsai YF, Lin S, et al: Studies on the immunomodulating and anti-tumor activities of Ganoderma lucidum (Reishi) polysaccharides. Bioorg Med Chem 12: 5595-5601, 2004. (Pubitemid 39304059)
3. Bao X, Liu C, Fang J and Li X: Structural and immunological studies of a major polysaccharide from spores of Ganoderma lucidum (Fr.) Karst. Carbohydr Res 332: 67-74, 2001. (Pubitemid 32441606)
4. Eo SK, Kim YS, Lee CK and Han SS: Possible mode of antiviral activity of acidic protein bound polysaccharide isolated from Ganoderma lucidum on herpes simplex viruses. J Ethnopharmacol 72: 475-481, 2000.
5. Li YQ and Wang SF: Anti-hepatitis B activities of ganoderic acid from Ganoderma lucidum. Biotechnol Lett 28: 837-841, 2006.
6. Li WJ, Nie SP, Chen Y, et al: Ganoderma atrum polysaccharide protects cardiomyocytes against anoxia/reoxygenation-induced oxidative stress by mitochondrial pathway. J Cell Biochem 110: 191-200, 2010.
7. Kabir Y and Kimura S: Dietary mushrooms reduce blood pressure in spontaneously hypertensive rats (SHR). J Nutr Sci Vitaminol (Tokyo) 35: 91-94, 1989. (Pubitemid 19107768)
8. Kabir Y, Kimura S and Tamura T: Dietary effect of Ganoderma lucidum mushroom on blood pressure and lipid levels in spontaneously hypertensive rats (SHR). J Nutr Sci Vitaminol (Tokyo) 34: 433-438, 1988.
9. Seto SW, Lam TY, Tam HL, et al: Novel hypoglycemic effects of Ganoderma lucidum water-extract in obese/diabetic (+db/+db) mice. Phytomedicine 16: 426-436, 2009.
10. Harhaji Trajkovic LM, Mijatovic SA, Maksimovic-Ivanic DD, et al: Anticancer properties of Ganoderma lucidum methanol extracts in vitro and in vivo. Nutr Cancer 61: 696-707, 2009.
11. Waterhouse DN: A novel combination of Chinese medicines to treat advanced cancers and lymphomas in rats. Chin Med 4: 22, 2009.
12. Mahajna J, Dotan N, Zaidman BZ, Petrova RD and Wasser SP: Pharmacological values of medicinal mushrooms for prostate cancer therapy: the case of Ganoderma lucidum. Nutr Cancer 61: 16-26, 2009.
13. Permuth-Wey J and Sellers TA: Epidemiology of ovarian cancer. Methods Mol Biol 472: 413-437, 2009.
14. Williams TI, Toups KL, Saggese DA, Kalli KR, Cliby WA and Muddiman DC: Epithelial ovarian cancer: disease etiology, treatment, detection, and investigational gene, metabolite, and protein biomarkers. J Proteome Res 6: 2936-2962, 2007. (Pubitemid 47310180)
15. Martin LP and Schilder RJ: Management of recurrent ovarian carcinoma: current status and future directions. Semin Oncol 36: 112-125, 2009.
16. Xu G, Bernaudo S, Fu G, Lee DY, Yang BB and Peng C: Cyclin G2 is degraded through the ubiquitin-proteasome pathway and mediates the antiproliferative effect of activin receptor-like kinase 7. Mol Biol Cell 19: 4968-4979, 2008.
17. Xu G, Zhong Y, Munir S, Yang BB, Tsang BK and Peng C: Nodal induces apoptosis and inhibits proliferation in human epithelial ovarian cancer cells via activin receptor-like kinase 7. J Clin Endocrinol Metab 89: 5523-5534, 2004. (Pubitemid 39518436)
18. Xu G, Zhou H, Wang Q, Auersperg Nand Peng C: Activin receptor-like kinase 7 induces apoptosis through up-regulation of Bax and down-regulation of Xiap in normal and malignant ovarian epithelial cell lines. Mol Cancer Res 4: 235-246, 2006.
19. Xie Y, Li S, Yee A, et al: Ganoderma lucidum extract inhibits tumour cell proliferation and induces tumour cell death. Enzyme Microb Technol 40: 177-185, 2006. (Pubitemid 44556768)
20. Zietarska M, Maugard CM, Filali-Mouhim A, et al: Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC). Mol Carcinog 46: 872-885, 2007. (Pubitemid 47549773)
21. Franken NA, Rodermond HM, Stap J, Haveman J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc 1: 2315-2319, 2006.
22. Tsang WP, Chau SP, Fung KP, Kong SK and Kwok TT: Modulation of multidrug resistance-associated protein 1 (MRP1) by p53 mutant in Saos-2 cells. Cancer Chemother Pharmacol 51: 161-166, 2003. (Pubitemid 36259477)
23. Yuen JW and Gohel MD: Anticancer effects of Ganoderma lucidum: a review of scientific evidence. Nutr Cancer 53: 11-17, 2005. (Pubitemid 43068549)
24. Weng CJ, Chau CF, Yen GC, Liao JW, Chen DH and Chen KD: Inhibitory effects of Ganoderma lucidum on tumorigenesis and metastasis of human hepatoma cells in cells and animal models. J Agric Food Chem 57: 5049-5057, 2009.
25. Hsu SC, Ou CC, Chuang TC, et al: Ganoderma tsugae extract inhibits expression of epidermal growth factor receptor and angiogenesis in human epidermoid carcinoma cells: In vitro and in vivo. Cancer Lett 281: 108-116, 2009.
26. Sadava D, Still DW, Mudry RR and Kane SE: Effect of Ganoderma on drug-sensitive and multidrug-resistant small-cell lung carcinoma cells. Cancer Lett 277: 182-189, 2009.
27. Muller CI, Kumagai T, O'Kelly J, Seeram NP, Heber D and Koeffler HP: Ganoderma lucidum causes apoptosis in leukemia, lymphoma and multiple myeloma cells. Leuk Res 30: 841-848, 2006. (Pubitemid 43816702)
28. Lu QY, Jin YS, Zhang Q, et al: Ganoderma lucidum extracts inhibit growth and induce actin polymerization in bladder cancer cells in vitro. Cancer Lett 216: 9-20, 2004. (Pubitemid 39410491)
29. Chui CH, Wong RS, Cheng GY, et al: Antiproliferative ability of a combination regimen of crocodile egg extract, wild radix ginseng and natural Ganoderma lucidum on acute myelogenous leukemia. Oncol Rep 16: 1313-1316, 2006.
30. Jiang J, Grieb B, Thyagarajan A and Sliva D: Ganoderic acids suppress growth and invasive behavior of breast cancer cells by modulating AP-1 and NF-κB signaling. Int J Mol Med 21: 577-584, 2008.
31. Thyagarajan A, Zhu J and Sliva D: Combined effect of green tea and Ganoderma lucidum on invasive behavior of breast cancer cells. Int J Oncol 30: 963-969, 2007.
32. Westphal S and Kalthoff H: Apoptosis: targets in pancreatic cancer. Mol Cancer 2: 6, 2003.
33. Ghobrial IM, Witzig TE and Adjei AA: Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 55: 178-194, 2005. (Pubitemid 40826487)
34. Jiang J, Slivova V, Valachovicova T, Harvey K and Sliva D: Ganoderma lucidum inhibits proliferation and induces apoptosis in human prostate cancer cells PC-3. Int J Oncol 24: 1093-1099, 2004.
35. Tang W, Liu JW, Zhao WM, Wei DZ and Zhong JJ: Ganoderic acid T from Ganoderma lucidum mycelia induces mitochondria mediated apoptosis in lung cancer cells. Life Sci 80: 205-211, 2006. (Pubitemid 44853986)
36. Lin SB, Li CH, Lee SS and Kan LS: Triterpene-enriched extracts from Ganoderma lucidum inhibit growth of hepatoma cells via suppressing protein kinase C, activating mitogen-activated protein kinases and G2-phase cell cycle arrest. Life Sci 72: 2381-2390, 2003.
37. Hermeking H, Lengauer C, Polyak K, et al: 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1: 3-11, 1997. (Pubitemid 127376388)
38. Bunz F, Dutriaux A, Lengauer C, et al: Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501, 1998. (Pubitemid 28538613)
39. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A and Oren M: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352: 345-347, 1991. (Pubitemid 21912356)
40. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B and Costa J: Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 89: 4495-4499, 1992.
41. Aggarwal BB and Shishodia S: Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71: 1397-1421, 2006.
42. Yang X, Fraser M, Abedini MR, Bai T and Tsang BK: Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by Akt. Br J Cancer 98: 803-808, 2008. (Pubitemid 351272611)
43. Yang X, Fraser M, Moll UM, Basak A and Tsang BK: Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res 66: 3126-3136, 2006.